<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653558</url>
  </required_header>
  <id_info>
    <org_study_id>LNB-2020</org_study_id>
    <nct_id>NCT04653558</nct_id>
  </id_info>
  <brief_title>Clinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis</brief_title>
  <official_title>Clinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis According to Diagnostic Certainty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this retrospective cohort study of patients with early Lyme neuroborreliosis (LNB),&#xD;
      clinical and microbiologic characteristics and long-term outcome of definite vs. possible LNB&#xD;
      were evaluated at a single university medical center in Slovenia. Severity of acute disease&#xD;
      and long-term outcome during a 12-month follow-up were assessed using a composite clinical&#xD;
      score based on objective clinical findings and subjective complaints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>composite clinical score</measure>
    <time_frame>follow-up for 12 months-post-treatment</time_frame>
    <description>Composite clinical score based on objective clinical findings and subjective complaints. The sum of subjective complaints and objective findings scored as 0=absent or 1=present represent severity of disease on admission or clinical outcome at follow-up, respectively. Maximum total score=31</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">311</enrollment>
  <condition>Lyme Disease</condition>
  <arm_group>
    <arm_group_label>definite LNB</arm_group_label>
    <description>patients with definite early Lyme neuroborreliosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>possible LNB</arm_group_label>
    <description>patients with possible early Lyme neuroborreliosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with definite or possible early Lyme neuroborreliosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  early Lyme neuroborreliosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not fulfilling study criteria for definite or possible Lyme neuroborreliosis&#xD;
&#xD;
          -  Alternative diagnosis during follow-up&#xD;
&#xD;
          -  Concomitant tick-borne encephalitis&#xD;
&#xD;
          -  Clinical symptoms/signs present for &gt;6 months&#xD;
&#xD;
          -  Data not available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University Medical center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Da≈°a Stupica</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lyme neuroborreliosis</keyword>
  <keyword>post-Lyme borreliosis symptoms</keyword>
  <keyword>antibiotic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Lyme Neuroborreliosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Only on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

